Lysis autologous melanoma cells tumor-infiltrating lymphocytes association clinical response Tumor-infiltrating lymphocytes TILs vitro medium clinical trials Surgery Branch National Cancer Institute patients metastatic malignant melanomas adoptive transfer autologous TILs time treatment TILs vitro lysis fresh autologous allogeneic melanoma cells Daudi cells Patients clinical response weeks Lysis autologous tumor cells TILs patients Tumor cells nonresponding patients sensitive allogeneic lymphokine-activated killer LAK cells difference TILs nonresponding patients lysis LAK-sensitive Daudi cells low cases TIL lysis autologous tumor cells due LAK cells observed association autologous tumor cell lysis TILs clinical response development culture methods lysis autologous tumors response rates TIL treatment regimen 